Recent advances in the treatment of systemic lupus erythematosus with belimumab in children
DENG Wei-Ping
Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410078, China (Luo P, Email: luoping1011@126.com)
Abstract：Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organs, and lupus nephritis (LN) is the most common renal complication of SLE. Belimumab is a fully humanized monoclonal antibody that can reduce the number of B cells, thereby reducing the formation of autoantibodies. Belimumab can improve SLE response index and SLE disease activity score and delay the progression of LN in both adults and children and thus plays an important role in the treatment of SLE and LN. This article reviews related research reports of belimumab used in the treatment of children and adults with SLE in China and overseas and analyzes the efficacy and safety of belimumab in pediatric patients, in order to provide a reference for the clinical application of belimumab in children with SLE.
Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(6): 736-745. PMID: 30926722. DOI: 10.1136/annrheumdis-2019-215089.
Al Sawah S, Zhang X, Zhu BJ, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort[J]. Lupus Sci Med, 2015, 2(1): e000066. PMID: 25861455. PMCID: PMC4378372. DOI: 10.1136/lupus-2014-000066.
Kleinmann JF, Tubach F, Le Guern V, et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus[J]. Autoimmun Rev, 2017, 16(6): 650-657. PMID: 28434948. DOI: 10.1016/j.autrev.2017.04.011.
Tsokos GC, Lo MS, Reis PC, et al. New insights into the immunopathogenesis of systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2016, 12(12): 716-730. PMID: 27872476. DOI: 10.1038/nrrheum.2016.186.
Tipton CM, Hom JR, Fucile CF, et al. Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: a B-cell immunomics approach[J]. Immunol Rev, 2018, 284(1): 120-131. PMID:29944759. PMCID:PMC6022284. DOI: 10.1111/imr.12660.
Baker KP, Edwards BM, Main SH, et al. Generation and characterization of lymphostat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator[J]. Arthritis Rheum, 2003, 48(11): 3253-3265. PMID: 14613291. DOI: 10.1002/art.11299.
Brunner HI, Abud-Mendoza C, Viola DO, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial[J]. Ann Rheum Dis, 2020, 79(10): 1340-1348. PMID: 32699034. PMCID: PMC7509523. DOI: 10.1136/annrheumdis-2020-217101.
Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2011, 377(9767): 721-731. PMID: 21296403. DOI: 10.1016/S0140-6736(10)61354-2.
Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2011, 63(12): 3918-3930. PMID: 22127708. PMCID: PMC5007058. DOI: 10.1002/art.30613.
Wallace DJ, Ginzler EM, Merrill JT, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2019, 71(7): 1125-1134. PMID: 30771238. PMCID: PMC6617785. DOI: 10.1002/art.40861.
Iaccarino L, Andreoli L, Bocci EB, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study[J]. J Autoimmun, 2018, 86: 1-8. PMID: 28935492. DOI: 10.1016/j.jaut.2017.09.004.
Tanaka Y, Bae SC, Bass D, et al. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea[J]. RMD Open, 2021, 7(2): e001629. PMID: 34215703. PMCID: PMC8256836. DOI: 10.1136/rmdopen-2021-001629.
Suso JP, Posso-Osorio I, Jiménez CA, et al. Profile of BAFF and its receptors' expression in lupus nephritis is associated with pathological classes[J]. Lupus, 2018, 27(5): 708-715. PMID: 29087261. DOI: 10.1177/0961203317739132.
Kraaij T, Arends EJ, van Dam LS, et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results[J]. Nephrol Dial Transplant, 2021, 36(8): 1474-1483. PMID: 32591783. PMCID: PMC8311580. DOI: 10.1093/ndt/gfaa117.
Tarr T, Dérfalvi B, Gy?ri N, et al. Similarities and differences between pediatric and adult patients with systemic lupus erythematosus[J]. Lupus, 2015, 24(8): 796-803. PMID: 25516474. DOI: 10.1177/0961203314563817.
Zhang FC, Bae SC, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea[J]. Ann Rheum Dis, 2018, 77(3): 355-363. PMID: 29295825. PMCID: PMC5867402. DOI: 10.1136/annrheumdis-2017-211631.
Ferreira JCOA , Trindade VC, Espada G, et al. Epidemiology and management practices for childhood-onset systemic lupus erythematosus patients: a survey in Latin America[J]. Clin Rheumatol, 2018, 37(12): 3299-3307. PMID: 30094748. DOI: 10.1007/s10067-018-4254-4.
Fontana F, Alfano G, Leonelli M, et al. Efficacy of belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report[J]. BMC Nephrol, 2018, 19(1): 276. PMID: 30342482. PMCID: PMC6196012. DOI: 10.1186/s12882-018-1066-3.
32 Nino A, Bass DL, Eriksson G, et al. Efficacy and safety of intravenous belimumab in children with systemic lupus erythematosus: an across-trial comparison with the adult belimumab studies[J]. Arthritis Rheum, 2019, 71(suppl 10): 5083-5085.
33 Sheikh S, Scheinberg M, Wei JCC, et al. Headline results for a phase 4, 52-week, randomised, double-blind, placebo-controlled study to assess adverse envents of special interest (AESI) in adults with active, autoantibody-positive system lupus erythematosus (SLE) receiving belimumab[J]. Ann Rheum Dis, 2019, 78: 266.
Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus[J]. Lupus, 2013, 22(2): 144-154. PMID: 23213069. DOI: 10.1177/0961203312469259.
Fredericks CA, Kvam KA, Bear J, et al. A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab[J]. Lupus, 2014, 23(7): 711-713. PMID: 24531080. DOI: 10.1177/0961203314524292.
Leblanc-Trudeau C, Masetto A, Bocti C. Progressive multifocal leukoencephalopathy associated with belimumab in a patient with systemic lupus erythematosus[J]. J Rheumatol, 2015, 42(3): 551-552. PMID: 25729044. DOI: 10.3899/jrheum.140577.
Benvenuti F, Gatto M, Doria A. A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab—comments on article by Fredericks et al[J]. Lupus, 2014, 23(13): 1445-1446. PMID: 25107935. DOI: 10.1177/0961203314545800.
Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis[J]. Ann Rheum Dis, 2020, 79(6): 713-723. PMID: 32220834. DOI: 10.1136/annrheumdis-2020-216924.
